Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 01.08.2022.

#Biotech
#healthcare
#primarycare
#hcsm
#healthconsumers
#Amazon
#digitalhealth
#Healthprivacy
#medicare
#RetailHealth

@JaredSHopkins shared
On Jul 26, 2022
A wave of new drugs to treat heart diseases from Novartis, Pfizer, Alnylam and others is starting to reach patients, as drugmakers work to revive a $48 billion category that once powered the industry https://t.co/KEbC1BB06B
Open
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

Drugmakers Hope New Heart Drugs Boost Sales, Revive Market

Merck, Novartis and others are seeking to revive the $48 billion market, which had shrunk after top-selling cholesterol and other drugs lost patent protection.

@HealthcareLdr shared
On Jul 27, 2022
RT @healthythinker: The #RetailHealth Battle Royale, Day 2 - @Amazon & @OneMedical https://t.co/IZ3OcZofcg #Amazon already entrenched in #healthcare seeks to add #primarycare & #medicare in the mix. #Healthinsurance next? #Healthprivacy will be #digitalhealth #healthconsumers #hcsm @Davidlaz https://t.co/bpFLmI4wvM
Open
The Retail Health Battle Royale in the U.S. – A Week-Long Brainstorm, Day 2 of 5 – Amazon and One Medical

The Retail Health Battle Royale in the U.S. – A Week-Long Brainstorm, Day 2 of 5 – Amazon and One Medical

Today we review the various viewpoints on Amazon’s announced acquisition of One Medical (ONEM, aka 1life Healthcare) which has been a huge story in both health care trade publications, ...

@jonathanrockoff shared
On Jul 31, 2022
The Manchin-Schumer climate, tax and healthcare bill would, for the first time, give the federal government the authority to negotiate how much it pays for some prescription drugs, ⁦@joewalkerWSJ⁩ reports https://t.co/0jXWPJBM8V
Open
U.S. Would Gain Power to Negotiate Drug Prices Under Manchin-Schumer Bill

U.S. Would Gain Power to Negotiate Drug Prices Under Manchin-Schumer Bill

The legislation would also cap out-of-pocket drug costs for Medicare beneficiaries at $2,000 a year.

@Dominic_Tyer shared
On Aug 1, 2022
RT @endpts: Don’t call it Operation Warp Speed 2.0, but Senate Democrats on Thursday proposed $22 billion in 2023 emergency supplemental funding for the next phase of the pandemic. https://t.co/n970eueTEm
Open
Senate proposes $16B to fund the next wave of Covid-19 vaccines, therapeutics in 2023

Senate proposes $16B to fund the next wave of Covid-19 vaccines, therapeutics in 2023

Don't call it Operation Warp Speed 2.0, but Senate Democrats on Thursday proposed $22 billion in 2023 emergency supplemental funding for the next phase of the pandemic, including $16 ...

@SWLifeSciences shared
On Jul 27, 2022
The U.S. Patent and Trademark Office recently issued a Notice of Allowance for clinical-stage #biotech company @AnixaBio's breast cancer vaccine technology. #Biotech Co. Granted New Patent for Breast Cancer Vaccine: https://t.co/ypPyyy6jON $ANIX #Stocks #Investments #BCCWW https://t.co/H9QWf894eT
Open
Biotech Co. Granted New Patent for Breast Cancer Vaccine Research Report

Biotech Co. Granted New Patent for Breast Cancer Vaccine Research Report

Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this ...

@SWLifeSciences shared
On Jul 29, 2022
Shares of @NervgenP traded 28% higher after it reported its NVG-291-R showed functional repair to damage from #ischemic #stroke seven days following the event. Drug Candidate Repairs Motor/Sensory Function in Stroke: https://t.co/CWU6nZDlTe $NGEN $NGENF #Biotech #Stocks https://t.co/LgWaf70pf6
Open
Drug Candidate Repairs Motor/Sensory Function in Stroke Trending Company

Drug Candidate Repairs Motor/Sensory Function in Stroke Trending Company

Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair ...

@Alnylam shared
On Jul 28, 2022
This morning, we reported Q2 2022 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM ET to discuss and a replay will be available following. Access the webcast and replay here: https://t.co/TPvqh2Wj00 $ALNY #RNAi #siRNA
Open
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals Press Release | Jul 28, 2022

@matthewherper shared
On Jul 26, 2022
RT @AndrewE_Dunn: I spent the past few months reporting this story out, learning about the infuriating gap between clinical success and commercial failure for SCID gene therapy. Check out Jakob's story here, which is playing out in many rare diseases beyond 'bubble boy' https://t.co/wTFtE7JbNR
Open
Jakob is 2 years old. He has a deadly disease. But drug companies won’t give him the cure — because they won’t make a big enough profit.

Jakob is 2 years old. He has a deadly disease. But drug companies won’t give him the cure — because they won’t make a big enough profit.

What's keeping kids with 'bubble boy' disease from living a normal life isn't their illness. It's the marketplace.

Read more:
weekly 01.08.2022
View archives
Back to home

Subscribe to Biotech - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy